A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a ...
A team of Chinese scientists has used targeted gene editing to develop rice that produces coenzyme Q10 (CoQ10), a vital ...
Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...
5h
Hosted on MSNCRISPR-Cas9 Off-Target Effects: Challenges and SolutionsThe CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
7h
Fintel on MSNEvercore ISI Group Upgrades CRISPR Therapeutics (CRSP)Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG (CRSP – Research Report), with ...
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results